(TIR) increased from 26.4% at baseline to 52.7% at Week 16 with iGlarLixi treatment.
Treatment satisfaction, measured using the (DM-SAT), showed a mean overall score increase from 0.59 at baseline to 0.78 at Week 16.
A total of 118 (95.9%) participants completed the DM-SAT at baseline, and 107 (87.0%) at Week 16.
Trends in improvement were observed across all four domains of treatment satisfaction: well-being, medical control, lifestyle, and convenience.
The improvement in TIR was positively associated with improvement in overall treatment satisfaction, though the correlation was weak (mean r = 0.14).
Simplified
AIMS: In Soli-CGM, treatment with iGlarLixi (insulin glargine 100 U/mL and lixisenatide 33 μg/mL) in insulin-naive adults with suboptimally controlled type 2 diabetes (T2D; haemoglobin A1c 9%-13% on ≥2 oral antihyperglycaemic agents (OADs) ± glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy) increased (TIR; primary endpoint) from 26.4% at baseline to 52.7% at Week 16. This exploratory analysis examined the impact of treatment with iGlarLixi on patient-reported treatment satisfaction.
MATERIALS AND METHODS: Soli-CGM was a single-arm, 16-week, multicentre, interventional, open-label, phase 4 study using blinded continuous glucose monitoring (CGM; FreeStyle Libre Pro) to assess glycaemic metrics (N = 124). CGM data were collected for a 2-week period before initiation of iGlarLixi, and after treatment with iGlarLixi (Weeks 14-16). Treatment satisfaction was assessed using the (DM-SAT, which comprises four domains: well-being, medical control, lifestyle and convenience), at baseline and end-of-treatment. Association of TIR and overall satisfaction (sum of all items) was also assessed.
RESULTS: Overall, 118 (95.9%) and 107 (87.0%) participants completed the DM-SAT at baseline and Week 16, respectively. Mean overall score increased by 0.18, from 0.59 (baseline) to 0.78 (Week 16). A trend in improvement in score was observed in all domains. Improvement in TIR had a positive, but weak, trend of association with improvement in overall treatment satisfaction (mean r = 0.14).
CONCLUSIONS: In people with T2D suboptimally controlled on ≥2 OADs ± GLP-1 RA, 16 weeks' treatment with iGlarLixi resulted in a trend of improvement in treatment satisfaction.
Key numbers
0.18
Increase in Overall Treatment Satisfaction Score
Mean score increased from 0.59 at baseline to 0.78 at Week 16.
26.4% to 52.7%
Increase in ()
improved significantly from baseline to Week 16.
107 of 123
Participant Completion Rate
Number of participants who completed the at Week 16.
Full Text
We can’t show the full text here under this license.
VNS reports receiving fees from Ascensia, Dexcom, Diabetes Care, Embecta, Genomelink, Insulet, LumosFit, Novo Nordisk, Sanofi and Tandem Diabetes Care for speaking, consulting or advising services. TD and LM are employees of, and may hold stocks/shares in, Sanofi. AR is an employee of Ividata, contracted by Sanofi. WHP reports receiving fees from Abbott Diabetes, Bigfoot, Dexcom, Eli Lilly, Embecta, Insulet, Novo Nordisk, Sanofi and Vertex for consulting, and research support from Abbott Diabetes and Dexcom.
